Skip to main content
Home
  • About
    • Board of Directors
    • Our Staff
    • Careers
      • Policies
      • Annual Reports
        • 2018 Annual Report
        • 2017 Annual Report
    • Programs
      • COVID-19 Hub
      • IMEDS Post Market Safety Studies
        • IMEDS Network Partners
        • IMEDS Research Portfolio
        • IMEDS Steering Committee
      • Expanded Access Navigator
      • FDA Patient Listening Sessions
    • News and Events
      • Annual Public Meeting
      • News
      • Events
      • Awards
    • COVID-19
    • facebook
    • twitter
    • linkedin
    • youtube
    Home
    • About
      • Board of Directors
      • Our Staff
      • Careers
      • Policies
      • Annual Reports
    • Programs
      • COVID-19 Hub
      • IMEDS Post Market Safety Studies
      • Expanded Access Navigator
      • FDA Patient Listening Sessions
    • News and Events
      • Annual Public Meeting
      • News
      • Events
      • Awards
    • COVID-19

    News

    Breadcrumb

    1. Home
    2. News and Events
    3. Updated FDA Guidance on Expanded Access
    • facebook
    • twitter
    • email
    • print

    Updated FDA Guidance on Expanded Access

    The FDA updated its guidance to clarify that listing in our Expanded Access Navigator Company Directory satisfies the 21st Century Cures Act requirement of making EA policies readily available. Read "How should we post our expanded access policy?" for detail.

     

    Subscribe for updates from the Reagan-Udall Foundation for the FDA

    Subscribe
    (202) 849 - 2075
    1900 L Street NW, Suite 835
    Washington, DC 20036
    admin@reaganudall.org
    • facebook
    • twitter
    • linkedin
    • youtube

    © Reagan-Udall Foundation for the FDA
    © Reagan-Udall Foundation for the FDA